A special 79-year-old man has received unparalleled access to Eli Lilly’s obesity drug.Millions of Americans are eagerly awaiting access to retatrutide, a powerful new drug from the pharmaceutical company. But one unidentified person has been able to gain premature access to the drug via the Food and Drug Administration’s “compassionate use” program, STAT reported Tuesday.The FDA program is designed to prioritize access to experimental drugs for patients with grave or life-threatening medical issues. And while the name of the individual is not known, several signs indicate that they are likely very well connected.A senior clinician at the National Institutes of Health, Ranganath Muniyappa, requested access to the drug for the unnamed patient in April. Muniyappa cited a diagnosis of refractory obesity with obstructive sleep apnea and pulmonary hypertension, a potentially life-threatening disease characterized by high blood pressure in the lungs. The request reportedly drew the attention of top health officials, which STAT noted was indicative of the patient’s influence.Based on the vague parameters of the patient’s identity, STAT reached out to the White House to see if the recipient could possibly be Donald Trump, who similarly suffers from obesity and has publicly expressed interest in obesity drugs. The White House did not explicitly deny the patient was Trump.When asked if Trump was the 79-year-old man in question, White House spokesperson Kush Desai did not say no, and instead referred STAT to the Department of Health and Human Services. (The president was 79 at the time of the request, and turned 80 earlier this month.)When asked if Trump had obstructive sleep apnea and pulmonary hypertension, Desai offered Trump’s latest medical evaluation as a counter, which he falsely claimed “covers this,” according to STAT. It does not—the memo makes no mention of either disease.HHS did not address the issue of the retatrutide application or the patient’s identity.“The FDA supports expanded access programs that can provide patients with serious or life-threatening conditions access to investigational treatments when no comparable or satisfying approved therapies are available,” HHS spokesperson Emily Hilliard told STAT. “Each request is reviewed on a case-by-case basis based on the clinical circumstances and applicable statutory and regulatory requirements.”In a public exchange with STAT over X later Tuesday morning, Desai specified that the application was “not for the president.” STAT reporter Lizzy Lawrence responded that she had asked several federal agencies multiple times on Monday but that no one had answered her question directly.Whoever the patient is, they had been previously treated with other obesity drugs, such as tirzepatide, though sources who spoke with STAT indicated the patient experienced only moderate weight loss as a result. Muniyappa reportedly recommended against bariatric surgery because of the patient’s age and co-morbidities.This story has been updated.
